The small GTPases H, K, and NRAS are molecular switches that are indispensable for proper 35 regulation of cellular proliferation and growth. Mutations in this family of proteins are 36 associated with cancer and result in aberrant activation of signaling processes caused by a 37 deregulated recruitment of downstream effector proteins. In this study, we engineered 38 novel variants of the Ras-binding domain (RBD) of the kinase CRAF. These variants bound 39 with high affinity to the effector binding site of active Ras. Structural characterization 40 showed how the newly identified mutations cooperate to enhance affinity to the effector 41 binding site compared to RBDwt. The engineered RBD variants closely mimic the interaction 42 mode of naturally occurring Ras effectors and as dominant negative affinity reagent block 43 their activation. Experiments with cancer cells showed that expression of these RBD variants 44 inhibits Ras signaling leading to a reduced growth and inductions of apoptosis. Using the 45 optimized RBD variants, we stratified patient-derived colorectal cancer organoids according 46
4
Ras activity, several affinity reagents based on protein scaffolds have been developed to 83 address different facets of Ras biology. For example, fibronectin-derived monobodies inhibit 84 signaling by disrupting the dimerization of H and KRAS at the plasma membrane [11] . 85
Interfering with Ras dimerization limits the growth of xenografts that inducibly express the 86 monobody [12] . An alternative strategy for inhibiting Ras signaling with engineered proteins 87 is to prevent the recruitment of downstream effectors or block the activation of Ras by GEFs. 88 To this end, affinity reagents have been generated that compete with Ras effectors by 89 selectively binding to the active or inactive state of oncogenic Ras [13] [14] [15] [16] [17] [18] [19] . However, several 90 required high concentrations to be effective in cells [16, 17, 20] , and their selectivity for 91 members of the Ras family is unknown. The limited effectiveness may be related to the 92 interaction of Raf family kinases with various Ras GPTases. Thus, a rationale for affinity 93 reagents with improved efficacy could be those that block interactions with multiple Ras 94 family members simultaneously. 95
An ideal affinity reagent that inhibits Ras function should avoid steric constraints by 96 precisely replicating effector binding to activated, GTP-bound Ras. Additionally, these affinity 97 reagents should have a high affinity to the effector binding site and the ability to 98 outcompete downstream effectors. Consequently, such an affinity reagent would act as 99 inhibitor of Ras signaling, which could be used to probe the biology of Ras inhibition in 100 cellular and patient-derived model systems. To derive an affinity reagent that fulfills these 101 criteria, we adapted our strategy of optimizing pre-existing intermolecular contacts [21, 22] 102 to the RBD of CRAF. We constructed a phage-displayed RBD library encoding mutations of 103 interface residues and selected for improved binding to active, GTP-bound Ras. Crystal 104 structures of complexes with activated HRAS G12V showed that the RBD variants (RBDvs) 105 precisely mimic effector binding, and the engineered mutations subtly improve 106 intermolecular contacts. Importantly, intracellular expression of individual RBDvs resulted in 107 impaired growth of various cancer cell lines due to a robust inhibition of Ras signaling and 108 the MAP kinase signaling cascade. Finally, in patient-derived organoids, the differential 109 effects of the RBDvs on cellular growth and metabolic activity revealed differences in Ras 110 dependency of colorectal tumor organoids, demonstrating that genetic data were 111 insufficient to predict responsiveness to Ras inhibition. The ability of the RBDvs to inhibit 112 growth of cells lacking activating mutations in Ras family members may relate to their Previous studies demonstrated that the CRAF-RBD is highly tolerant to mutations and can be 120 computationally engineered to preferentially bind inactive states of Ras [18, 23, 24] . To 121 optimize the interface of the RBD to active Ras, we analyzed existing crystal structures of 122
Ras:RBD complexes [5, 25, 26] . In total, we identified 14 residues that make sidechain 123 contacts to the switch-1 region of the Ras effector binding site. These residues are located 124 on the 1-2 hairpin and 1 helix, and span two distinct regions of the CRAF-RBD. To 125 achieve a moderate to low mutation rate that does not alter the binding mode nor impair 126 the structure of the RBD, we used a soft randomization strategy that allowed 70% of the 127 wild-type nucleotides and 10% of the non-wild-type nucleotides to occur at any codon 128 position encoding the targeted residues ( Fig. 1A) . Additionally, we replaced three unpaired 129 cysteines at position 81, 95, and 96 of the RBD with serine residues to prevent dimerization 130 of phage-displayed proteins and improve overall presentation of the RBDvs. Our final library 131 contained more than 2x10 9 unique RBDvs presented on the surface of filamentous phage 132 and subsequent selection by phage display yielded 5 variants with improved binding to 133 surface immobilized GTPS-loaded HRAS (Fig. 1B) . The selected variants show a conserved 134 mutational pattern, indicating a shared binding mode to activated Ras. Strikingly, the 135 mutation Gln 66 to Glu is highly enriched in all 5 variants, indicating that this mutation has a 136 crucial role in mediating the increased affinity. Coincidentally, the mutation from Val 88 to 137 Arg, previously shown to increase the affinity of RBD to HRAS [27] , was also present in all 5 138
variants. An Arg 89 to His mutation occurred in four of the five RBDvs. 139
After purification as His-tagged proteins, we tested if the engineered RBDvs 140 outcompeted CRAF-RBDwt binding to GTPS-loaded KRAS in vitro (Fig. 1C) . Relative to 141 RBDwt, all engineered variants showed an enhanced ability to compete off GTPS KRAS in 142 solution. A similarly enhanced competitive ability of the RBDvs was observed using the Ras 143 association domain (RA) of Ral Guanine Nucleotide Dissociation Stimulator (RalGDS) instead 144 6 of the CRAF-RBDwt (Supplementary Fig. 1A) . Because RBDv1 and RBDv12 performed best in 145 these experiments, we focused our further analysis on these two variants. 146
Affinity measurements confirmed that RBDv1 and RBDv12 have improved binding 147 properties relative to RBDwt for activated HRAS with K d s of ~ 3 nM versus ~60 nM and 148 strongly preferred binding to activated, GTPS loaded HRAS with negligible binding to the 149 GDP-bound form (Fig. 1D) . In control experiments, we confirmed that His-tagged HRAS 150 GTPS does not bind to GST-loaded sensors or empty sensors alone ( Supplementary Fig. 1B) , 151 indicating that the slow off rate is not due to non-specific binding of HRAS to GST or the 152 sensor material. 153 154
The engineered RBDvs mimic effector binding to active Ras 155
To understand the structural basis for improved binding, we crystallized HRAS G12V in 156 complex with RBDv1 at 2.9 Å and RBDv12 at 3.15 Å resolution in an active conformation ( Fig.  157 2A, Supplementary Table 1 ). Structural analysis revealed that the RBDvs engaged the 158 effector binding site of HRAS through a canonical binding mode [5] with only minor shifts to 159 the center of mass positions and rotation angle (1.8 Å/15˚ and 2.0 Å/16˚ for RBDv1 and 160 RBDv12, respectively). Similar to the canonical binding mode of RBDwt, 2 of the RBDvs 161 forms an extended intermolecular -sheet with 2 of HRAS ( Supplementary Fig. 2A) . In 162 addition, helices 1 of both RBDwt and RBDvs form direct contacts with switch 1 residues in 163 Ras ( Fig. 2A) . Inspection of direct contact interface reveals that the conserved RBDvs 164 mutations of Gln 66 to Glu, Val 88 to Arg, and Arg 89 to His result in a rewiring of the hydrogen 165 (H)-bonding pattern to the Asp 38 and Tyr 40 side chains in HRAS ( Fig. 2B ). This change in H-166 bonding pattern together with steric effects involving Ile 21 in HRAS and Val 88 to Arg in RBDvs 167 appears responsible for a shift of the 1-helix of the RBDvs relative to that observed in 168 RBDwt (Fig. 2C) . In summary, our combinatorial approach to RBD-interface engineering 169 identified three key mutations that work together to improve contacts to residues in the 170 switch 1 region of Ras in an active conformation. Because the binding mode of RBDvs to 171 HRAS overlaps completely with RBDwt, the RBDvs are expected to outcompete binding of 172 Ras effectors that engage this common binding site. 173
174
The RBDvs bind Ras GTPases in cells 7
We tested the intracellular specificity of the RBD variants using mass spectrometry. We 176 immunoprecipitated hemagglutinin (HA)-tagged RBDvs and HA-RBDwt that were inducibly 177 expressed in stably transduced colon carcinoma HCT 116 cells ( Supplementary Fig. 3A and  178   B ). HCT 116 are heterozygous for the activating mutant KRAS G13D. Strikingly, relative to 179 RBDwt, RBDv1 and RBDv12 displayed up to 5500-fold enrichment of peptides from 180 endogenous KRAS4B G13D isoform ( Fig. 3A, Supplementary Table 2 ). The prevalence of 181 peptides originating from the constitutively active KRAS4B G13D isoform suggests that the 182 RBDvs preferentially interact with Ras GTPases, which are in an active conformation. 183
We also detected peptides from other Ras family GTPases, although these were ~10-184 fold less abundant than KRAS4B G13D peptides. Analysis of the primary sequences of the 185 other Ras family members that interacted with the RBDvs showed that these Ras family 186 members share a common effector binding site ( Fig. 3B) . In particular, the detected peptides 187 were from Ras family members containing D 38 and Y 40 residues in their respective switch-1 188 region, which we identified as key interaction residues for the RBDvs (Fig. 2B) . Thus, the 189 immunoprecipitation data showed that RBDvs bind to their intended targets, Ras proteins, in 190 cells, and exhibit the highest affinity for active Ras. 191 Consequently, these results suggested that the RBDvs are dominant-negative affinity 192 reagents that will not only impair signaling through constitutive active Ras mutants but also 193 other Ras GTPases in the active conformation. Thus, the RBDvs have the potential to inhibit 194 multiple Ras-mediated pathways to Raf activation. Furthermore, the simultaneous inhibition 195 of multiple Ras GTPases is potentially an efficient way to control the proliferation of cells 196 with heterozygous KRAS genotypes, which confer resistance to MEK inhibitors [28]. 197 198
RBDvs inhibit activation of the ERK and AKT pathways resulting in reduced metabolic 199 activity and apoptosis 200
To test if the RBDvs act as inhibitors of Ras-dependent signaling processes, we probed whole 201 cell lysates from cell lines expressing HA-tagged RBDvs or RBDwt with antibodies detecting 202 the phosphorylation state of kinases downstream of Ras proteins. Specifically, we examined 203 the effect of inhibition of Ras/Raf interaction in cell lines of different cancer origins and with 204 different Ras mutations ( Supplementary Table 3 ). Immunoblot analysis showed that the 205 RBDvs reduced the phosphorylation of the growth signal-activated ERK1/2 in HCT 116, Mia 206 PaCa-2, A549, and H1299 cells (Fig. 4A) . The corresponding control experiments with RBDwt, 207 8 despite its higher expression, did not reduce ERK1/2 phosphorylation, indicating that the 208 improved affinity of the RBDvs for active Ras isoforms is required to suppress activation of 209 these downstream kinases. 210
Reduced activity of MAP kinase pathway often results in reduced cell viability. 211 Therefore, we measured ATP content, as an indicator of metabolic activity and viability, and 212 monitored growth curves, as an indicator of proliferation. In all 4 cell lines, inhibition of 213 effector binding to active Ras by the RBDvs reduced cell viability (ATP content) ( Fig. 4B) , 214 indicating that the RBDvs disrupt Ras signaling in cells from different cancer backgrounds. 215 Importantly, RBDwt control had only minimal effects on the viability of all 4 cell lines. Five-216 day growth curves measured with HCT116 cells confirmed that the RBDvs, but not RBDwt, 217 inhibited proliferation ( Fig. 4C) . 218
Ras signaling not only mediates proliferative responses, but these GTPases also 219 promote cell survival. In the presence of the RBDvs, HCT 116 cells exhibited reduced 220 phosphorylation of Ser 473 in the serine/threonine kinase AKT, indicating that PI3 kinase 221 pathway is inhibited ( Fig. 4D) . Together, the reduced MAP kinase and PI3 kinase pathway 222 activity could not only reduce cellular metabolic activity and proliferation but could also 223 increase apoptosis. We monitored HCT116 cells expressing either RDBvs or RBDwt for 224 annexin V staining as an indicator of apoptotic cells ( Fig. 4E, Supplementary Fig. 4) . 225
Quantification of annexin V staining by flow cytometry revealed that HCT116 cells expressing 226 the RBDvs had significantly increased number of apoptotic cells compared to non-induced 227 controls and compared to induced cells expressing RBDwt. In summary, these results 228 showed that the RBDvs inhibit the ERK and PI3K signaling pathway, resulting in growth 229 reduction in a wide range of cancer cell lines and inducing apoptosis in HCT116 cells. 230 231
RBDvs lead to reduced growth in patient-derived colorectal cancer organoids 232
To investigate whether the characteristics of our RBDvs in cell culture can be translated into 233 a patient-derived model, we used tumor organoids with known Ras mutation status isolated 234 from surgically removed colorectal carcinoma from 7 patients [29] ( Table 1) . After 235 transduction with the doxycycline-inducible lentiviral constructs, we compared cell viability 236 and growth of organoids, cultured in Matrigel and expressing RBDvs or RBDwt. We 237 evaluated by immunoblot of organoid lysates ERK and AKT phosphorylation in response to 238 doxycycline-induced expression of the RBDvs or RBDwt (Fig. 5A, Supplementary Figure 5A) . 239 9
The different organoids showed different sensitivity to the inhibitory effects of the RBDvs on 240 these two kinases. For example, P17T with wild-type KRAS showed little effect of RBDv12, 241 and P6T with KRAS G12C showed a stronger effect of the RBDvs on ERK1/2 phosphorylation 242 than on Akt phosphorylation ( Fig. 5A) . P18T with wild-type KRAS showed little effect of 243 either RBDv1 or RBDv12 (Supplementary Figure 5A ). This is consistent with different cancers 244 having diverse adaptive signaling pathways and different signaling dependencies. 245
Despite the variability in the effects on kinase phosphorylation, subsets of the 246 organoids with mutant Ras (P6T and P28T) and those with wild-type Ras (P17T and P24bT) 247 had reduced viability when expressing either RBDv1 or RBDv12, as indicated by reduced 248 metabolic activity (ATP content) ( Fig. 5B) . In addition, the effect of RBDvs on cell viability 249 correlated with decreased colony size as determined by bright field microscopy ( Fig. 5C) . 250 Importantly, quantification of the colony size indicated that the inhibitory RBDvs significantly 251 reduced growth when compared to non-induced organoids ( Fig. 5D ). However, growth of 252 P18T and P20T, both with wild-type KRAS, and P26T with KRAS G12V was unaffected by 253 either RBDv1 or RBDv12 (Supplementary Figure 5B) . Thus, KRAS mutant status was 254 insufficient to predict sensitivity to the growth-inhibiting effects of Ras inhibition ( Table 1) . 255
Our data indicated that the RBDvs classify colorectal cancer samples for Ras dependency. 256
The difference in responsiveness to RBDvs was not related to downstream activation of 257 growth signaling by mutant BRAF or PI3K in these organoids, because we tested organoids 258 that are wild-type for BRAF and PI3K [29] . In conclusion, the RBDvs decreased the growth of 259 four patient-derived organoid lines, indicating that inhibiting the interactions between 260 activated Ras proteins and their effectors may be a valid strategy in cancer therapy. 261
262
Discussion 263 By engineering the Ras/Raf interface of the CRAF-RBD, we developed potent and highly 264 selective inhibitors of activated Ras that outcompete the binding of signaling effectors. The 265 selectivity of the engineered variants for an active conformation of Ras occurred through 266 molecular contacts to a minimal epitope composed of switch 1 residues at the center of the 267 effector binding site. High affinity was achieved by a subtle rewiring and optimization of the 268 hydrogen bond pattern at the interface between the RBD and HRAS. Because the effector 269 binding site is conserved amongst Ras family members, we detected interactions between 270 the RBDvs and other Ras GTPases with nearly identical sequence composition in the switch 1 271 region. This multispecificity may be beneficial for therapeutic applications based on the 272 RBDvs, because cancer cells often develop resistance to highly specific targeted therapies 273 [30, 31] . The ability to inhibit multiple related Ras family members specifically in the active 274 conformation may prevent a bypass or network rewiring that enables resistance, may 275 interfere with other pathways that collectively provide cancer cells a growth advantage, or 276 may sensitize cancer cells to other therapeutics. 277
In cellular experiments, expression of RBDvs efficiently reduced ERK and AKT 278 phosphorylation and cellular growth and triggered apoptosis in cell lines from different 279 cancer backgrounds. We applied the RBDvs to a clinical research question and showed that 280 the RBDvs could be used as a tool to delineate Ras dependency in colorectal cancer 281 carcinoma (CRC) [29] . In CRC several different signaling pathways have been implicated in 282 disease pathogenesis [32] . However, the extent and heterogeneity of genetic alterations in 283 CRC makes it difficult to analyze the contribution of individual pathways to the proliferative 284 phenotype [29] . More importantly, this diversity makes defining an effective treatment 285 strategy challenging. We showed that the inhibition observed in adherent cell culture 286 experiments translates to patient-derived colorectal cancer organoids: Several of the 287 organoids exhibited reduced growth when expressing either RBDv1 or RBDv12. However, 288 indicative of their varying degree of Ras dependency, not all organoids responded equally 289 well to Ras inhibition by the inhibitory RBDvs. Unexpectedly, the Ras dependency did not 290 correspond to the presence of mutant Ras, showing that genetic information is insufficient 291 to predict therapeutic response. Thus, the RBDvs can be used to facilitate functional 292 classification of Ras dependency in intestinal tumor organoids, which has the potential to 293 drive therapeutic strategies. 294
Although the RBDvs are a unique tool for studying Ras-dependent signaling 295 processes, several intracellular affinity reagents targeting GTP-bound Ras have been 296 reported [13, [15] [16] [17] . Compared with the previously reported Ras-targeted reagents, the 297 RBDvs were effective at lower concentrations. For example, the affinity reagent R11. Ras effectors to inhibit Ras-dependent signaling events [16] . The cell-penetrating TMab4 307 RT11 antibody targeting the switch 1 site of Ras proteins also requires high concentrations to 308 effectively inhibit Ras-mediated signaling events [17] . Two designed ankyrin repeat proteins 309 (DARPins) with specificity for either the GDP-bound inactive state (K27) or the GTP-bound 310 active state (K55) of Ras have been reported [13] . Both DARPins inhibit Ras signaling in 311 transfected HEK293T cells and lentivirus transduced HCT 116 cells; however, it remains to be 312 seen if the observed effects occur in other cell types and organoids. The lower affinity of K55 313 (167 nM) compared with that of CRAF-RBDwt (~ 60-80 nM) for GTP-bound Ras also suggests 314 that a high concentration will be required to compete for endogenous effectors in a cellular 315
context. 316
In contrast to these other Ras interaction inhibitors, the intracellular inhibition of Ras 317 signaling by the RBDvs does not show similar avidity or concentration dependent effects. 318
Indeed, we observed robust inhibition in several different cell lines and organoids despite 319 the expression of the RBDvs was always less than the corresponding wild-type control. The 320
RBDvs exhibited preferential binding to active Ras proteins, indicating high selectivity not 321 only for Ras proteins with a shared effector binding site but also for these proteins in their 322 active conformation. Most likely, the other interaction inhibitors, especially TMab4 RT11 323 that also binds the switch-1 sequence, may also have similar multispecificity for Ras proteins. 324
This potential property of the other affinity reagents should be further examined. 325
A common challenge in all these efforts is the effective delivery of intracellular 326 affinity reagents to the cytosol. Consequently, various intracellular protein delivery 327 platforms, such as cell-penetrating peptides, nanocarrier, liposomes, polymer and 328 nanoparticle-stabilized nanocapsules (reviewed in [33]), are actively under investigation. 329
Another promising strategy for the delivery of proteins into mammalian cells is the use of 330 bacterial toxins, which can deliver a wide array of passenger proteins spanning a range of 331 sizes, structures, and stabilities [34] . For example, a recent report shows that a fusion protein 332 of the RBDwt is able to pass through the channel of a tripartite toxin complex (Tc toxins) 333 derived from bacterial pathogens. Thus, due to its small size and favorable charge 334 distribution the RBD-scaffold may be particularly suited for delivery by Tc toxins [35] . In 335 future, these and other platforms can enable targeted delivery of proteins into cells to 336 12 realize the potential of protein-based therapeutics with intracellular sites of action. RBDvs 337 would then be a candidate for delivery to test in treating diseases associated with 338 unchecked Ras activity. 339
Material and Methods 340

Ras expression, purification and nucleotide exchange 341
The human HRAS (AA 1-166) and KRAS (AA 1-169, isoform B) proteins were expressed as GST-342 fusions from pGEX-6P-1 plasmids for selection experiments and as His-tag fusions from pET-343 53 plasmids for in vitro competition and binding assays. Plasmids were used to transform E. 344
coli Rosetta(DE3) cells and individual colonies were handled essentially as written before [22] , 345 except that all buffers were supplemented with 5 mM MgCl 2 . Briefly, resulting cultures from 346 individual colonies were inoculated into Luria Broth (LB) media and protein expression was 347 induced at OD 600 =0.8 with 0.5 mM IPTG. After overnight incubation at 16 °C, bacterial pellets 348 were resuspended in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM PMSF and 5 mM MgCl 
Construction of a phage-displayed CRAF-RBD library 360
For phage library construction, Ras-binding domain (RBD) of human CRAF kinase (AA 55-131) 361 was cloned into the phagemid pNE [21] and cysteines at position 81, 95 and 96 of the RBD 362 were mutated to serines using site-directed mutagenesis [36] . Afterwards, two degenerate 363 oligonucleotides were used to introduce mutations at 2 regions of the RBD gene by site-364 directed mutagenesis. Oligonucleotides were soft-randomized as described before [21, 22] . 365
The nucleotide ratio was adjusted to 70 % of the wt nucleotide represented N1 = A, N2 = C, 366 N3 = G and N4 = T and 10 % of each of the other three nucleotides. 367
Oligonucleotide 1: GAT GAC AAA AGC AAC N1N2N4 ATC N2N3N4 GTT N4N4N2 TTG CCG AAC 368 N1N1N3 N2N1N1 N1N3N1 ACA N3N4N3 GTC N1N1N4 GTG CGA AAT GGA ATG 369
Oligonucleotide 2: CAT GAC TGC CTT ATG N1N1N1 N3N2N1 CTC N1N1N3 N3N4N3 N2N3N3 370 N3N3N2 CTG CAG CCA GAG TGC 371 14
The resulting library was used to electroporate E. coli SS320 cells using established methods 372 resulting in 2.2x10 9 independent RBD variants [37] . 373
374
RBD variant selection against activated HRAS 375
Library pool of phage displaying individual RBD variants were harvested by precipitation with 376 PEG/NaCl (20 % PEG-8000 (w/v), 2.5 M NaCl) and resuspended in PBT buffer (1x PBS, 1 % 377 BSA, 0.1 % Tween 20) supplemented with 5 mM MgCl 2 . Immobilization of GTPS-loaded GST-378 tagged HRAS and subsequent binding selections were done essentially as described before 379 [22] , except that all buffers were supplemented with 5 mM MgCl 2 . In brief, 4 wells of a 96 380 well Maxisorp microtiter plate (NUNC) were coated with 100 µl of 2 µM GST-tagged GTPS-381 loaded HRAS in dialysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM DTT and 5 mM 382 and incubated over night at 37 °C. In each successive selection round, the selection 388 stringency was increased by 2 additional washing steps and. To avoid unspecific binding 389 towards the GST-tag, a GST counter-selection was performed starting with round 2. 390 Additionally, after 3 rounds of selection, phage binding and washing was done at room 391 temperature and the concentration of coated GST-tagged GTPS-loaded HRAS was reduced 392 to 0.5 µM. After five rounds of enrichment, individual RBD variants with improved binding 393 properties towards active HRAS were identified by clonal phage ELISA as described [37] . In 394 brief, phage displaying individual RBD variants were prepared from single colonies of 395 bacteria harboring phagemids encoding RBDvs and transferred to 384-well Maxisorp plates 396 immobilized with GST-tagged GTPS-labelled HRAS (0.5 µM) and blocked with BSA, as 397 described previously. As negative controls, wells were coated with GST or only blocked with 398 BSA. After incubation, washing and developing, positive clones were further analysed by 399 sequencing. RBDvs bacterial pellets were resuspended in 50 mM HEPES pH 7.5, 300 mM NaCl, 5 % glycerol, 445 1 mM PMSF, 1 mM TCEP and lysed by homogenization. The lysate was cleared by 446 centrifugation at 4 °C for 40 minutes at 18,000 g. Protein was bound to glutathione affinity 447 resin (GE Healthcare), eluted by cleavage of the GST-tag with TEV, concentrated and then 448 buffer exchanged by size exclusion chromatography (SEC) using a Superdex75 24 ml column 449 (GE healthcare) equilibrated in 50 mM HEPES pH 7.5, 50 mM NaCl, 5 % glycerol, 10 mM MgCl 2 , 450 1 mM TCEP. 451 HRAS G12V bacterial pellets were resuspended in 50 mM HEPES pH7.5, 300 mM NaCl, 5 mM 452 EDTA, 5 % glycerol, 1 mM PMSF, 1 mM TCEP and lysed by homogenization. The lysate was 453 clarified by centrifugation at 4 °C for 40 minutes at 18,000 g. Protein was bound to glutathione 454 affinity resin (GE Healthcare), washed with 50 mM HEPES pH 7.5, 300 mM NaCl, 25 mM 455 imidazole, 5 % glycerol, 1 mM TCEP and eluted by cleavage of the GST-tag with TEV, 456 concentrated and then buffer exchanged by SEC using a Superdex75 24 ml column 457 equilibrated in 50 mM HEPES pH7.5, 300 mM NaCl, 5 mM EDTA, 5 % glycerol, 1 mM TCEP. 458 GMP-PNP loading on HRAS G12V was carried out by incubating purified HRAS G12V with 10-459 fold excess of GMP-PNP for 80 min at 4 ˚C followed by the addition of 30-fold excess of MgCl 2 460 for 120 min at 4 ˚C. 461
The RBDvs:HRAS G12V complexes were obtained by mixing RBDvs and GMP-PNP loaded HRAS 462 G12V at equal molar ratio for 60 min at 4 ˚C followed by SEC using a Superdex75 24 ml column 463 equilibrated in 50 mM HEPES pH 7.5, 50 mM NaCl, 10 mM MgCl 2 , 5 % glycerol, 1 mM TCEP. All 464 fractions corresponding to co-elution of HRAS G12V with RBDvs were pooled and 465 concentrated to 12.2 mg/ml, then flash frozen in liquid nitrogen. Protein concentration was 466 estimated by UV-Vis absorption spectroscopy using a NanoDrop spectrophotometer Fisher Scientific). 468 469 Protein crystallography, data collection and structural analysis. 470
The RBDvs:HRAS G12V complexes were crystallized at 20 ˚C in sitting-drop by mixing 0.5 µL of 471 complexes (450 μM, 12.2 mg/ml) with 0.5 µL of mother liquor of 0.1 M sodium cacodylate pH 472 6.5, 200 mM ammonium sulphate, 30 % PEG 4000 or mother liquor of 0.1 M sodium citrate 473 pH 5.6, 200 mM ammonium sulphate, 30 % PEG 4000 for RBDv1:HRAS G12V and RBDv12:HRAS 474 G12V, respectively. X-ray diffraction data were collected on a flash-frozen crystal cryo-475 protected in mother liquor containing 25 % glycerol at 100 K on station 24-ID-C, NE CAT 476 beamline, Advanced Photon Source (APS). Data reduction was performed using XDS package 477 Two 10 cm dishes per construct (RBDwt, v1 and v12) were seeded with 2x10 6 /ml stable HCT 497 116 cells and RBDvs expression was induced 24 h later with doxycycline. After 24 h induction, 498 18 cells were scraped into 1x PBS and washed twice with 1x PBS. After centrifugation, the cell 499 pellets were resuspended in lysis buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 % NP-40, 5 500 mM MgCl 2 , 5 % glycerol and protease inhibitor cocktail [Roche] ) and incubated for 20 min at 501 4 °C with end-over-end rotation. The lysates were centrifuged, supernatants were transferred 502 to 20 µl pre-equilibrated anti-HA affinity matrix (Roche) and incubated for 40 min at 4 °C. 503
Beads were washed 2 times with 500 µl lysis buffer. Elution was performed by the addition of 504 20 µl 2x SDS-sample buffer to the beads and incubation for 3 min at 95 °C. 5 µl of samples 505 were analysed by immunoblotting using antibodies against endogenous Ras, HA-tag and 506 GAPDH (#3965, #2999 and #8884, respectively; all from Cell Signaling Technology). Sample 507 preparation for in-gel digest was done as described before [46] . In brief, supernatants were 508 loaded onto SDS-polyacrylamide gel and the gel was stained using InstantBlue (Expedeon). Gel 509 lanes were cut into pieces and subsequently washed, destained and dehydrated. Proteins Carbamidomethyl at cysteine residues was set as a fixed modification, while oxidation at 548 methionine and acetylation at the N-terminus were defined as variable modifications. The 549 minimal peptide length was set to seven amino acids and the false discovery rate for proteins 550 and peptide-spectrum matches to 1 %. The match-between-run feature was used with a time 551 window of 0.7 min. Relative label-free quantification of proteins was done using the MaxLFQ 552 algorithm integrated into MaxQuant [51] . The minimum LFQ ratio count was set to 2 and the 553 FastLFQ option was enabled. 554
For subsequent analysis, the Perseus software (1.5.3.0) [52] was used and first filtered for 555 contaminants and reverse entries and proteins that were only identified by site. The LFQ 556 intensities were logarithmized to base 2 and grouped into duplicates. To overcome the missing 557 value problem in immunoprecipitation data, proteins that were quantified less than 2 times 558 in one of the experimental groups were discarded from further analysis. Missing values were 559 imputed column-wise by a down-shifted (median-1.8) Gaussian distribution mimicking the 560 detection limit of the mass spectrometer. 561 562 20 Metabolic activity assay 563 1000 cells of each stable cell line were seeded in a 96 well plate in duplicates. The following 564 day, expression was induced by the addition of doxycycline. Corresponding control wells were 565 not induced. Cell viability was assayed 120 h after induction using CellTiter-Glo (Promega). 566
Luminescence signals of induced wells were normalized to uninduced well data. FACSCanto II flow cytometer (BD Biosciences) and data were processed by FlowJo software 596 (FlowJo, LLC). Gating was done based on viable and single cells that were identified on the 597 basis of scatter morphology. 598 599
Organoid cultures 600
Human tumor colon organoid samples were obtained from a published colorectal cancer 601 organoid biobank [29] . Resection tissues were obtained with written informed consent, and 602 following approval by the ethics committees of the Diakonessen Hospital, Utrecht. Tissue was 603 obtained with written informed consent and following approval, according to the guidelines 604 of the University Cancer Center (UCT), Frankfurt. Organoid cultures were established and 605 maintained as described previously [53] . Tumor organoids were maintained in medium lacking 606
Wnt3a. The organoid lines were transduced as described [54] with lentivirus expressing N-607 terminally HA-tagged RBDwt, RBDv1 or RBDv12 (as above). Three days after transduction, 608 organoids were selected with 1 μg/mL puromycin in the culture medium. For cell viability 609 assays, the cells were seeded in Matrigel either following mechanical dissociation or 610 enzymatic single cell dispersal using TrypLE Express reagent (Gibco). 2 μg/mL doxycycline was 611 added 1 day after seeding. After 3 days cell viability was measured using CellTiter-Glo reagent 612 (Promega). All experiments were measured as technical triplicates and the experiments were 613 repeated at least twice each. 614
For quantification of organoid size, light microscopy pictures were taken at a 2x resolution 615 after 2-6 days of doxycycline exposure, as indicated. The diameter (µm) of all viable organoids 616 in one picture of each condition was measured using ImageJ. Viable organoids were identified 617 as refringent, while dark structures surrounded by cell debris were excluded from the analysis. 618
The quantification was performed on two independent experiments. 619 620
Statistical methods 621
Data are presented as the mean ± standard deviation (SD). The comparisons between RBDwt 622 and RBDvs were made by an unpaired t test using GraphPad Prism software. For statistical 623 analysis of the quantification results of organoid sizes, a Mann-Whitney U-test was 624 performed using GraphPad Prism software. The level of significance was set at * P< 0.05, ** P< 625 0.01 and *** P< 0.005. 626 
